8-K
filed June 24, 2026, 8:56 AM ET
ticker CNTA
CIK 0001847903
M&A
confidence high
sentiment neutral
materiality 1.00
Centessa acquired by Eli Lilly for $38/sh plus up to $9/sh CVR
Centessa Pharmaceuticals plc
- Acquisition closed June 24, 2026; Centessa became wholly owned subsidiary of Lilly.
- Shareholders received $38.00 cash per share plus one CVR worth up to $9.00 on milestones.
- All outstanding equity awards cashed out based on $38.00 consideration; CVRs issued.
- Centessa terminated its Oxford Finance loan facility and Leerink ATM sales agreement.
- CEO, board, and other officers resigned; Christopher Stokes and Kristina Wright appointed directors.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Samarth Kulkarni departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mary Lynne Hedley departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Raphael Deferiere departed as Executive Officer at Centessa Pharmaceuticals plc.
- Action
- ceased to serve
- Role
- Executive Officer
Exact text from the filing
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Christopher Stokes was appointed as Director at Centessa Pharmaceuticals plc.
- Action
- appointed
- Role
- Director
Exact text from the filing
Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mathias Hukkelhoven departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Crowley departed as Executive Officer at Centessa Pharmaceuticals plc.
- Action
- ceased to serve
- Role
- Executive Officer
Exact text from the filing
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mario Alberto Accardi departed as Chief Executive Officer and Director at Centessa Pharmaceuticals plc.
- Action
- ceased to serve
- Role
- Chief Executive Officer and Director
Exact text from the filing
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Francesco De Rubertis departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stephen Kanes departed as Executive Officer at Centessa Pharmaceuticals plc.
- Action
- ceased to serve
- Role
- Executive Officer
Exact text from the filing
Mario Alberto Accardi, Ph.D. (Chief Executive Officer and Director), John Crowley, Stephen Kanes, M.D., Ph.D., and Raphael Deferiere ceased to serve in their capacities as executive officers of Centessa.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Arjun Goyal departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brett Zbar departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kristina Mignon Wright was appointed as Director at Centessa Pharmaceuticals plc.
- Action
- appointed
- Role
- Director
Exact text from the filing
Christopher Stokes and Kristina Mignon Wright were appointed as directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Carol Stuckley departed as Director at Centessa Pharmaceuticals plc.
- Action
- ceased serving
- Role
- Director
Exact text from the filing
each of Francesco De Rubertis, Mario Alberto Accardi, Arjun Goyal, Mary Lynne Hedley, Mathias Hukkelhoven, Samarth Kulkarni, Carol Stuckley and Brett Zbar ceased serving as a member of the board of directors of Centessa
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.